---
title: Towards Early Detection of Breast Cancer in High Risk Population
nct_id: NCT05268913
overall_status: UNKNOWN
sponsor: University of Aberdeen
study_type: OBSERVATIONAL
primary_condition: Breast Cancer
countries: United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05268913.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05268913"
ct_last_update_post_date: 2022-03-07
last_seen_at: "2026-05-12T06:55:00.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Towards Early Detection of Breast Cancer in High Risk Population

**Official Title:** Robust EArly Detection of bReast Cancer in hIgh riSK Premenopausal Population Using Novel Lipid Based Imaging Methods

**NCT ID:** [NCT05268913](https://clinicaltrials.gov/study/NCT05268913)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 120
- **Lead Sponsor:** University of Aberdeen
- **Conditions:** Breast Cancer
- **Start Date:** 2022-03-01
- **Completion Date:** 2024-05-01
- **CT.gov Last Update:** 2022-03-07

## Brief Summary

Breast cancer is a major and growing health challenge, and the leading cause of cancer in women. As population obesity rates increase, the number of new breast cancer diagnosis continues to rise. Despite treatment advances, breast cancer remains an important cause of premature mortality, taking women in the prime of life. Although underlying susceptibility caused by mutation in the genes including BRCA1/2 is increasingly identified, current pre-symptomatic screening for the general population and those at high genetic risk remains sub-optimal, with high false negative and positive rates.

Alteration of breast lipid composition has been observed by us and others in patients with breast cancer and is thought to precede onset. We have developed and tested a novel method to allow a standard 3T MRI scanner to perform quantitative 3D mapping of specific lipid molecules in the breast.

We will investigate if this method can detect very early breast cancers, and compare the amount and spread of lipid composition in breast tissue of premenopausal women with very high genetic risk of breast cancer, women with breast cancer and women with obesity.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

\-

Women with BRCA1/2 genes:

* female 18-55 years old, premenopausal
* BRCA 1/2 gene carriers
* not having any metabolic disorders (e.g., diabetes)
* not on any long term medications that may affect lipid metabolism (e.g., statins)
* BMI \< 30

Women with breast cancer (no obesity):

* females 18-55 years old, premenopausal
* confirmed diagnosis of invasive ductal carcinoma of the breast
* not having any metabolic disorders (e.g., diabetes)
* not on any long term medications that may affect lipid metabolism (e.g., statins)
* BMI \< 30

Women with breast cancer (obesity):

* BMI \> 30
* otherwise as women with breast cancer

Women with obesity:

* females 18-55 years old, premenopausal
* not having any metabolic disorders (e.g., diabetes)
* not on any long term medications that may affect lipid metabolism (e.g., statins)
* BMI \> 30

Exclusion Criteria:

* females under 18 or over 55 years old, postmenopausal
* males
* have metabolic disorders (e.g., diabetes)
* on long term medications that may affect lipid metabolism (e.g., statins)
* contraindicated for MR investigation (poor renal function and metal implants)
* (for patients) concurrent cancer in other sites
* (for patients) started hormone treatment, chemotherapy or breast surgery
* non-English speakers
```

## Arms

- **Women with BRCA1/2 genes**
- **Women with breast cancer**
- **Women with obesity**

## Interventions

- **MRI scan** (DIAGNOSTIC_TEST) — Participants will undertake a magnetic resonance imaging scan.
- **Blood test** (BIOLOGICAL) — Participants will undertake a fasting blood test.

## Primary Outcomes

- **Amount of lipid composition in the breast** _(time frame: One hour)_ — The percentage of monounsaturated fatty acids, polyunsaturated fatty acids and saturated fatty acids relative to total lipid will be measured using magnetic resonance imaging (MRI) scanner software and MATLAB computer programme.

Unit of Measurement: %.
- **Spatial distribution (skewness) of lipid composition in the breast** _(time frame: One hour)_ — Skewness measures the asymmetry in distribution. The skewness of lipid composition in the breast will be measured using MRI scanner software and MATLAB computer programme.

Unit of Measurement: unitless.
- **Spatial distribution (entropy) of lipid composition in the breast** _(time frame: One hour)_ — Entropy measures the randomness in distribution. The entropy of lipid composition in the breast will be measured using MRI scanner software and MATLAB computer programme.

Unit of Measurement: unitless.
- **Spatial distribution (kurtosis) of lipid composition in the breast** _(time frame: One hour)_ — Kurtosis measures the peakedness in distribution. The kurtosis of lipid composition in the breast will be measured using MRI scanner software and MATLAB computer programme.

Unit of Measurement: unitless.

## Locations (1)

- Aberdeen Biomedical Imaging Centre, Aberdeen, Aberdeenshire, United Kingdom

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `locations.aberdeen biomedical imaging centre|aberdeen|aberdeenshire|united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05268913.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05268913*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*